Prognostic value of cytokines and chemokines in addition to the GRACE Score in non-ST-elevation acute coronary syndromes.

BACKGROUND Increased cytokine and chemokine levels are associated with cardiovascular events in patients with non-ST-elevation acute coronary syndromes (ACS), but the incremental prognostic value of these inflammatory markers is not known. We determined if cytokine and chemokine assessment adds prognostic information to the GRACE Score in patients with ACS. METHODS Five cytokines (interleukin (IL)-1beta, IL-6, IL-10, IL-12p70, and tumor necrosis factor (TNF)-alpha soluble receptor I), five chemokines (IL-8, CCL5, CXCL9, CCL2, and CXCL10) and C-reactive protein (CRP) were measured at admission of 87 patients admitted with ACS. RESULTS During hospitalization, the incidence of cardiovascular events was 13% (7 deaths, 1 nonfatal acute myocardial infarction, and 3 refractory unstable angina). Individuals who developed events had significantly greater levels of CRP, IL-1beta, IL-12, TNF-alpha, IL-8, CXCL9 and CCL2, compared with those free of events. Thus, these markers were used to build an Inflammatory Score, by the input of one point for each of these variables above the 75th percentile. After adjustment for the GRACE Score, the Inflammatory Score independently predicted events (OR=1.80; 95% CI=1.12-1.88). Incorporation of the Inflammatory Score into the GRACE Score promoted a C-statistics improvement from 0.77 (95% CI=0.58-0.96) to 0.85 (95% CI=0.71-1.0). Net reclassification improvement obtained with GRACE-Inflammatory Score was 13% (P=0.007), indicating a significant reclassification. When only CRP was incorporated into GRACE, the increase on C-statistics was not relevant (from 0.77 to 0.80). CONCLUSION Cytokines and chemokines measured at admission add prognostic information to the GRACE Score in patients admitted with ACS.

[1]  A. Yan,et al.  Understanding physicians' risk stratification of acute coronary syndromes: insights from the Canadian ACS 2 Registry. , 2009, Archives of internal medicine.

[2]  N Rifai,et al.  Clinical efficacy of an automated high-sensitivity C-reactive protein assay. , 1999, Clinical chemistry.

[3]  I. Penttilä,et al.  C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-α in the prognostic classification of unstable angina pectoris , 2001 .

[4]  T. Kılıç,et al.  Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome , 2006, Heart.

[5]  Nikolaos Laoutaris,et al.  Prognostic Value of C‐Reactive Protein, Fibrinogen, Interleukin‐6, and Macrophage Colony Stimulating Factor in Severe Unstable Angina , 2002, Clinical cardiology.

[6]  Pedro de Araújo Gonçalves,et al.  TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. , 2005 .

[7]  D. Morrow,et al.  The future of biomarkers in the management of patients with acute coronary syndromes , 2008, Current opinion in cardiology.

[8]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[9]  M. Halinen,et al.  C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. , 2001, Annals of medicine.

[10]  M. Sabatine,et al.  Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines. , 2006, Circulation.

[11]  Sidney C. Smith,et al.  MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .

[12]  L. Correia,et al.  Does high-sensitivity C-reactive protein add prognostic value to the TIMI-Risk Score in individuals with non-ST elevation acute coronary syndromes? , 2007, Clinica chimica acta; international journal of clinical chemistry.

[13]  R. Califf,et al.  Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. , 2007, Journal of the American College of Cardiology.

[14]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[15]  Carlos Aguiar,et al.  TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. , 2005, European heart journal.

[16]  P. Kovanen,et al.  Prognostic usefulness of plasma monocyte/macrophage and T-lymphocyte activation markers in patients with acute coronary syndromes. , 2004, The American journal of cardiology.

[17]  Chen,et al.  Simultaneous Quantification of Six Human Cytokines in a Single Sample Using Microparticle-based Flow Cytometric Technology. , 1999, Clinical chemistry.

[18]  A. Jaffe,et al.  Risk stratification for heart failure and death in an acute coronary syndrome population using inflammatory cytokines and N-terminal pro-brain natriuretic peptide. , 2007, Clinical chemistry.

[19]  E. Antman,et al.  Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes , 2003, Circulation.

[20]  J. Herlitz,et al.  C‐reactive protein, interleukin‐6, secretory phospholipase A2 group IIA and intercellular adhesion molecule‐1 in the prediction of late outcome events after acute coronary syndromes , 2007, Journal of internal medicine.

[21]  A. Yan,et al.  Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. , 2007, European heart journal.

[22]  P. Delves,et al.  The immune system. Second of two parts. , 2000, The New England journal of medicine.

[23]  J. Kaski,et al.  Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients: a factor analysis approach. , 2007, Atherosclerosis.

[24]  C. Heeschen,et al.  Serum Level of the Antiinflammatory Cytokine Interleukin-10 Is an Important Prognostic Determinant in Patients With Acute Coronary Syndromes , 2003, Circulation.

[25]  P. Doyle,et al.  Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. , 2003, Clinical chemistry.

[26]  M. Brockhaus,et al.  Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. , 1992, The Journal of clinical investigation.

[27]  A. Hamsten,et al.  Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome , 2007, Heart.

[28]  P. Järemo,et al.  Interleukin-6 and neutrophils are associated with long-term survival after acute myocardial infarction. , 2008, European journal of internal medicine.

[29]  G. Sanz,et al.  Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. , 2002, American heart journal.

[30]  H. Putter,et al.  CC Chemokine Ligand-5 (CCL5/RANTES) and CC Chemokine Ligand-18 (CCL18/PARC) Are Specific Markers of Refractory Unstable Angina Pectoris and Are Transiently Raised During Severe Ischemic Symptoms , 2007, Circulation.

[31]  Á. Avezum,et al.  Predictors of hospital mortality in the global registry of acute coronary events. , 2003, Archives of internal medicine.

[32]  G. Lip,et al.  Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. , 2005, Blood.

[33]  H. Putter,et al.  CCL3 (MIP-1 alpha) levels are elevated during acute coronary syndromes and show strong prognostic power for future ischemic events. , 2008, Journal of molecular and cellular cardiology.

[34]  T. Ueland,et al.  Chemokines and Cardiovascular Risk , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[35]  J. Kaski,et al.  Interleukin-18/interleukin-10 ratio is an independent predictor of recurrent coronary events during a 1-year follow-up in patients with acute coronary syndrome. , 2007, International journal of cardiology.

[36]  A. Rebuzzi,et al.  Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. , 1999, Circulation.

[37]  P. Delves,et al.  The Immune System , 2000 .